Search | WHO COVID-19 Research Database

1.

Current Status and Prospects of Vaccines based on DDS Technology.

Kawai, A.; Hirai, T.; Yoshioka, Y..

Drug Delivery System ; 37(5):402-411, 2022.

Article in Japanese | EMBASE | ID: covidwho-2265819

ABSTRACT

The development of DDS technology has contributed critically to the unprecedentedly rapid requirement for vaccines against COVID-19. LNP-based mRNA vaccines represent a subset of DDS emerging DDS technology. Despite the groundbreaking nature of these vaccines, they are yet to be perfected and as such, new technologies are being developed to optimize these vaccines. This review will focus on exploring one of the modalities of recombinant protein vaccines and will introduce various findings on the enhancement of vaccine efficacy using antigen modification technologies, including VLPs and Fc-fusion proteins, and adjuvant improvements.Copyright © 2022, Japan Society of Drug Delivery System. All rights reserved.

2.

Current Status and Prospects of Vaccines based on DDS Technology.

Kawai, A.; Hirai, T.; Yoshioka, Y..

Drug Delivery System ; 37(5):402-411, 2022.

Article in Japanese | EMBASE | ID: covidwho-2265818

ABSTRACT

The development of DDS technology has contributed critically to the unprecedentedly rapid requirement for vaccines against COVID-19. LNP-based mRNA vaccines represent a subset of DDS emerging DDS technology. Despite the groundbreaking nature of these vaccines, they are yet to be perfected and as such, new technologies are being developed to optimize these vaccines. This review will focus on exploring one of the modalities of recombinant protein vaccines and will introduce various findings on the enhancement of vaccine efficacy using antigen modification technologies, including VLPs and Fc-fusion proteins, and adjuvant improvements.Copyright © 2022, Japan Society of Drug Delivery System. All rights reserved.

3.

Current Status and Prospects of Vaccines based on DDS Technology.

Kawai, A.; Hirai, T.; Yoshioka, Y..

Drug Delivery System ; 37(5):402-411, 2022.

Article in Japanese | EMBASE | ID: covidwho-2265817

ABSTRACT

The development of DDS technology has contributed critically to the unprecedentedly rapid requirement for vaccines against COVID-19. LNP-based mRNA vaccines represent a subset of DDS emerging DDS technology. Despite the groundbreaking nature of these vaccines, they are yet to be perfected and as such, new technologies are being developed to optimize these vaccines. This review will focus on exploring one of the modalities of recombinant protein vaccines and will introduce various findings on the enhancement of vaccine efficacy using antigen modification technologies, including VLPs and Fc-fusion proteins, and adjuvant improvements.Copyright © 2022, Japan Society of Drug Delivery System. All rights reserved.

4.

Adapting to the dynamic landscape of the COVID-19 pandemic: Proposed study design approaches for a postauthorization safety study for Pfizer-BioNtech COVID-19 vaccine in the United States

Gilsenan, A. W.; Kawai, A. T.; Fuller, C. C.; De Luise, C.; Layton, J. B.; Johannes, C. B.; Brown, J.; Platt, R..

Pharmacoepidemiology and Drug Safety ; 31:617-618, 2022.

Article in English | Web of Science | ID: covidwho-2083654

5.

Capacity for identifying Janssen AD26.COV2.S COVID19 vaccination in four US health insurance and state immunization information system databases: Preparation for a post authorization safety study

Fuller, C. C.; Kawai, A. T.; Haynes, K.; Coughlin, K.; Reynolds, J.; Hawrusik, R.; Horgan, C.; Calingaert, B.; Johannes, C. B.; Layton, J. B.; Peterson, A.; Praet, N.; Willame, C.; Yost, E.; Brannan, C.; McMahill-Walraven, C. N.; Guzman, M.; Jamal-allial, A.; Nair, V.; Seals, R.; Wang, F.; Selvan, M.; Ma, Q. L.; Platt, R.; Gilsenan, A. W.; Brown, J..

Pharmacoepidemiology and Drug Safety ; 31:620-620, 2022.

Article in English | Web of Science | ID: covidwho-2083635

ABSTRACT

ABSTRACT

ABSTRACT

SEND TO:

SELECTION OF CITATIONS

SEARCH DETAIL